Zhang Chonghui
NIBR Biologics Center, Novartis Institutes for BioMedical Research.
Methods Mol Biol. 2012;901:117-35. doi: 10.1007/978-1-61779-931-0_7.
Hybridoma technology has long been a remarkable and indispensable platform for generating high-quality monoclonal antibodies (mAbs). Hybridoma-derived mAbs have not only served as powerful tool reagents but also have emerged as the most rapidly expanding class of therapeutic biologics. With the establishment of mAb humanization and with the development of transgenic-humanized mice, hybridoma technology has opened new avenues for effectively generating humanized or fully human mAbs as therapeutics. In this chapter, an overview of hybridoma technology and the laboratory procedures used routinely for hybridoma generation are discussed and detailed in the following sections: cell fusion for hybridoma generation, antibody screening and characterization, hybridoma subcloning and mAb isotyping, as well as production of mAbs from hybridoma cells.
长期以来，杂交瘤技术一直是生产高质量单克隆抗体（mAb）的卓越且不可或缺的平台。源自杂交瘤的单克隆抗体不仅作为强大的工具试剂，而且已成为发展最为迅速的治疗性生物制品类别。随着单克隆抗体人源化技术的建立以及转基因人源化小鼠的发展，杂交瘤技术为有效生产人源化或完全人源的治疗性单克隆抗体开辟了新途径。在本章中，将对杂交瘤技术以及常规用于产生杂交瘤的实验室程序进行概述，并在以下各节中详细讨论：用于产生杂交瘤的细胞融合、抗体筛选与鉴定、杂交瘤亚克隆及单克隆抗体的亚型鉴定，以及从杂交瘤细胞生产单克隆抗体。
